1500-355 Burrard Street

Vancouver, BC V6C 2G8 

Phone: +1 (844) 448-2580

Email (Business Development):

Member Sector: Biopharmaceuticals

Vitaeris is a clinical stage biopharmaceutical company dedicated to the development of a novel investigational approach to address antibody mediated rejection. Antibody mediated rejection has been recognized as the principal cause of late graft loss in solid organ transplant recipients. Our focus is on Clazakizumab, a potent humanized best-in-class monoclonal antibody targeting the cytokine interleukin-6 (IL-6)